vTv Therapeutics wins FDA Breakthrough Therapy designation for type 1 diabetes treatment
A Triad clinical-stage biopharmaceutical company has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes.
With a company focus on the development of orally administered treatments for type 1 diabetes and psoriasis, High Point-based vTv Therapeutics Inc. (Nasdaq: VTVT) created the treatment as a novel, oral, investigational once-daily glucokinase activator.
Breakthrough Therapy…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Source Type: news
More News: Diabetes | Diabetes Type 1 | Endocrinology | Food and Drug Administration (FDA) | Health Management | Insulin | Psoriasis